Impact News +++ Stimmrechtsanteile News: AIXTRON SE (EQS) +++ AIXTRON Aktie -3,36%

ASTELLAS Aktie

>ASTELLAS Aktienkurs

9.354 EUR +2.2% (Tradegate)

Ask: 9.38 EUR / 533 Stück

Bid: 9.194 EUR / 544 Stück

Tagesumsatz: 163 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ASTELLAS Aktie über LYNX handeln

Intraday

1 Jahr

>ASTELLAS Performance

1 Woche: +2,7%

1 Monat: -3,6%

3 Monate: +8,0%

6 Monate: +10,3%

1 Jahr: -13,5%

laufendes Jahr: -1,4%

>ASTELLAS Aktie

Name:

ASTELLAS PHARMA INC.

Land:

Japan

Sektor:

Gesundheit

ISIN/ Wkn:

JP3942400007 / 856273

Symbol/ Ticker:

YPH (Frankfurt)

Kürzel:

FRA:YPH, ETR:YPH, YPH:GR

Index:

Nikkei225

Webseite:

https://www.astellas.com/

Profil:

Astellas Pharma Inc. is a global pharmaceutical co..
>Volltext..

Marktkapitalisierung:

16500.82 Mio. EUR

Unternehmenswert:

20482.04 Mio. EUR

Umsatz:

11581.33 Mio. EUR

EBITDA:

3028.1 Mio. EUR

Nettogewinn:

485.68 Mio. EUR

Gewinn je Aktie:

0.27 EUR

Schulden:

5296.41 Mio. EUR

Liquide Mittel:

1282.58 Mio. EUR

Operativer Cashflow:

1448.28 Mio. EUR

Bargeldquote:

0.19

Umsatzwachstum:

16.08%

Gewinnwachstum:

376.7%

Dividende je Aktie:

0.45 EUR

Dividendenrendite:

4.61%

Dividendenschätzung:

4.86%

Div. Historie:

29.09.25 - 0.22400819€
28.03.25 - 0.2279274€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

ASTELLAS

Letzte Datenerhebung:

20.10.25

>ASTELLAS Kennzahlen

Aktien/ Unternehmen:

Aktien: 1791.13 Mio. St.

Frei handelbar: 95.74%

Leerverk. Aktien: -

Rückkaufquote: 0.03%

Mitarbeiter: 13643

Umsatz/Mitarb.: 0.8 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 7.35%

Bewertung:

KGV: 34.57

KGV lG: 18.06

KUV: 1.49

KBV: 1.89

PEG-Ratio: 0.1

EV/EBITDA: 6.76

Rentabilität:

Bruttomarge: 74.94%

Gewinnmarge: 4.19%

Operative Marge: 16.03%

Managementeffizenz:

Gesamtkaprendite: 2.31%

Eigenkaprendite: 5.17%

>ASTELLAS Peer Group

Es sind 53 Aktien bekannt.

>ASTELLAS Chart & Kurs - Tradegate

>ASTELLAS News

20.10.25 - 04:36	Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study (AFX)
	NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma U.S. Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination wi......

20.10.25 - 04:00	Astellas Reports Sustained GA Reduction With Long-Term IZERVAY Treatment In GATHER2 Extension Study (AFX)
	TOKYO (dpa-AFX) - Astellas Pharma Inc. announced the first results from the open-label extension (OLE) of its Phase 3 GATHER2 study, revealing that monthly treatment with IZERVAY (avacincaptad peg......

16.10.25 - 22:03	Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome (GlobeNewswire EN)
	The 2022 Option Agreement between Astellas and Taysha has expired...

15.10.25 - 02:03	Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society (PR Newswire)
	TOKYO, Oct. 14, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be......

14.10.25 - 10:24	Astellas′ Phase 2 Study GLEAM Study Of Zolbetuximab In Pancreatic Cancer Misses Primary Endpoint (AFX)
	TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) on Tuesday said the Phase 2 GLEAM study of zolbetuximab in metastatic pancreatic cancer failed to meet its primary endpoint of overall survival (OS).......

09.10.25 - 13:06	Biopharma Leaders Advance the Future of Life Sciences at Veeva Commercial Summit Europe (PR Newswire)
	Industry gathers to explore Veeva AI innovations and exchange ideas with companies including Astellas, Bayer AG, Boehringer Ingelheim, LEO Pharma, Moderna, and MSD BARCELONA, Spain, Oct. 9, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Astellas, Bayer AG, Boehringer......

09.10.25 - 01:30	Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting (PR Newswire)
	Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas")......

01.10.25 - 08:03	Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025 (PR Newswire)
	- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs - - Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer selected for presentation in......

29.09.25 - 08:03	Astellas Announces Top Management Personnel Change (PR Newswire)
	TOKYO, Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its Top Management structure, effective October 1, 2025. Nick Eshkenazi, current Chief Digital & Transformation Officer (CDTO),......

12.08.25 - 13:00	Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 11:48	Pfizer′s Padcev Plus Keytruda Extends Bladder Cancer Survival (Bloomberg)
	The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.'s blockbuster immunotherapy Keytruda extended the lives of patients with a hard-to-treat form of the disease....

31.07.25 - 03:36	Japan′s Astellas Pharma hits 8-mth high on upbeat Q1 earnings (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.25 - 10:12	Astellas Pharma Profit Up In Q1 (AFX)
	TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY), a pharmaceutical company, on Wednesday announced that profit attributable to Owners of the parent increased in the first quarter compared with the p......

28.07.25 - 14:31	Astellas Employee Makes No Appeal against Conviction (Nippon)
	Beijing, July 28 (Jiji Press)--A Japanese employee of Astellas Pharma Inc. of Japan, who has been sentenced to three years and six months in prison for espionage in China, did not appeal the ruling by a deadline of Monday, officials at the Japanese Embassy in Beijing said. The employee in his 60s will serve the sentence. He was detained by Chinese authorities in March 2023 just before re......

21.07.25 - 19:36	China urged Astellas employee to take plea bargain on spy charge: source (Nikkei)
	Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

19.07.25 - 11:36	Astellas Employee Intends Not to Appeal Conviction in China (Nippon)
	Beijing, July 19 (Jiji Press)--A Japanese employee of Astellas Pharma Inc. in his 60s, who was sentenced to three years and six months in prison for espionage in China on Wednesday, has no intention to appeal the ruling for now, informed sources said Saturday. As China uses a two-tier court system, those who are dissatisfied with the first ruling can appeal to a higher court. In the Aste......

19.07.25 - 02:30	China′s jailing of Astellas employee could have gone differently: ex-envoy (Nikkei)
	Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

17.07.25 - 12:01	Japan Urges China to Release Expats after Spy Conviction (Nippon)
	Tokyo, July 17 (Jiji Press)--Japan expressed disappointment Thursday after a Chinese court convicted a Japanese employee of Astellas Pharma Inc. of espionage, and called for the swift release of the employee, as well as other Japanese expatriates being held in China on similar charges. The guilty ruling, issued Wednesday, was "extremely regrettable," Japanese Deputy Chief Cabinet Secretary ......

17.07.25 - 06:03	Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "P (PR Newswire)
	- Supporting Korean Startups' Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program - TOKYO, July 17, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas")......

16.07.25 - 19:36	Astellas Pharma sentencing highlights China risks for corporate Japan (Nikkei)
	Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: gedanken . . . ein geschwätziger spatzenschwarm . . . kaum gelandet . . . schon wieder weg. - Klaus Wieser

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram